Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ADCT
ADC THERAPEUTICS S.A.
NYSE
$1.14
▲ UP 1.79% (0.02)

KEY STATISTICS

Market Cap$145.00 M
52w High$4.98
52w Low$0.78
Dividend Yield—
Frequency—
P/E-1.73
Volume2.58M
Shares Out.127.19M

COMPANY

LEADERSHIP

Ameet Mallik
CHIEF EXECUTIVE
Ameet Mallik

COMPENSATION 2026

Salary$776,084
Stock Awards$1,046,500
Incentive Plan Pay$582,063
All Other Comp.$48,503
Total$2,453,150

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 18, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
191

PRICE TARGET

Target High$5.00
Target Low$2.00
Target Median$3.50
Target Consensus$3.50

UPCOMING EARNINGS

DateNov 10, 2026
DayTuesday
Rev. Est.$18.87M
NOV
10
TUE

PRICE

$1.14 ▲ UP 1.79% (+$0.02)
$1.10$1.13$1.15$1.179:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM1.14

About ADC Therapeutics S.A.

https://www.adctherapeutics.com ↗

ADC Therapeutics SA is a Swiss biotech company developing antibody drug conjugates for hematological cancers and solid tumors, with multiple products in clinical trials including ZYNLONTA and camidanlumab tesirine.

INDUSTRY

Biotechnology

A PRODUCT ADC THERAPEUTICS S.A. IS KNOWN FOR

ZYNLONTA® (loncastuximab tesirine-lpyl)
ZYNLONTA® (loncastuximab tesirine-lpyl)

ZYNLONTA is an FDA-approved antibody-drug conjugate targeting CD19, used to treat relapsed or refractory large B-cell lymphoma, marking ADC Therapeutics' first commercial product and focus on targeted oncology therapies.

COMPETITORS

COMPETITOR
GILD COMPARE
GMAB COMPARE
PFE COMPARE
STRO COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$15.75M $22.31M ▲$20.03M ▼$18.63M ▼
Royalty Revenue$677K $746K ▲$818K ▲$614K ▼
License Revenues— $0 — —

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$15.75M $22.31M ▲$20.03M ▼$18.63M ▼
EMEA$677K $746K ▲$818K ▲$614K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
44
LISTED HERE
8
RANKED BY POSITION SIZE
IWM
0.00% · 2.7M
VTWO
0.00% · 604.3K
R2SC.L
0.00% · 150.8K
XRSG.L
0.00% · 75.9K
RSSL
0.00% · 50.8K
URTY
0.00% · 4.4K
FSEG
0.05% · 3.4K
SC0K.DE
0.00% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
62.32%
HOLDERS
143
TOP 12 OF 143 · RANKED BY POSITION SIZE
Redmile Group, LLC
15.7M sh · $55.3M
Tcg Crossover Management, LLC
11.4M sh · $42.71M
Prosight Management, LP
8.5M sh · $29.93M
Point72 Asset Management, L.P.
8.1M sh · $32.54M
Blackrock, Inc.
6.3M sh · $23.44M
Orbimed Advisors LLC
5.9M sh · $23.63M
Eventide Asset Management, LLC
5.7M sh · $21.38M
Nantahala Capital Management, LLC
5.6M sh · $20.99M
Morgan Stanley
3.8M sh · $14.3M
Blackrock Inc.
3.6M sh · $11.23M
Millennium Management LLC
3.1M sh · $11.7M
Goldman Sachs Group Inc
1.7M sh · $6.2M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Zaki Mohamed
Purchase · 213.9K shares
2026-06-30
★
OFFICER: CHIEF LEGAL OFFICER
GRAHAM PETER J
Purchase · 221.1K shares
2026-06-30
★
OFFICER: CHIEF FINANCIAL OFFICER
Carmona Jose
Purchase · 203.7K shares
2026-06-30
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
MALLIK AMEET
Purchase · 675.0K shares
2026-06-30

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
NEUTRAL 1
SECTOR PERFORM 1
3 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY HC Wainwright & Co. NEUTRAL RBC Capital SECTOR PERFORM

SECTORS PEERS

PEERPRICE
ALMS$22.38COMPARE
OMER$18.61COMPARE
LXRX$2.29COMPARE
FDMT$14.67COMPARE
AUTL$2.34COMPARE
BCYC$4.20COMPARE
NMRA$1.39COMPARE
QSI$0.78COMPARE